Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1978 3
1979 3
1981 3
1983 1
1987 1
1994 4
1996 1
1997 3
1998 6
1999 3
2000 6
2001 4
2002 4
2003 3
2004 8
2005 7
2006 5
2007 5
2008 1
2009 1
2011 1
2012 1
2013 5
2014 3
2015 1
2016 1
2017 1
2018 2
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 16899515

86 results
Results by year
Filters applied: . Clear all
Page 1
Hemodialysis acutely improves hepatic CYP3A4 metabolic activity.
Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Nolin TD, et al. J Am Soc Nephrol. 2006 Sep;17(9):2363-7. doi: 10.1681/ASN.2006060610. Epub 2006 Aug 9. J Am Soc Nephrol. 2006. PMID: 16899515 Free article.
Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.
Volpe DA, Tobin GA, Tavakkoli F, Dowling TC, Light PD, Parker RJ. Volpe DA, et al. Regul Toxicol Pharmacol. 2014 Mar;68(2):297-303. doi: 10.1016/j.yrtph.2013.10.006. Epub 2013 Oct 30. Regul Toxicol Pharmacol. 2014. PMID: 24184159
Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB, Norenberg J, Boyd A, Raj D, Chan LN. Pai AB, et al. Clin Ther. 2007 Dec;29(12):2699-705. doi: 10.1016/j.clinthera.2007.12.024. Clin Ther. 2007. PMID: 18201586 Clinical Trial.
Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal disease.
Tsujimoto M, Nagano Y, Hosoda S, Shiraishi A, Miyoshi A, Hiraoka S, Furukubo T, Izumi S, Yamakawa T, Minegaki T, Nishiguchi K. Tsujimoto M, et al. Toxins (Basel). 2013 Aug 19;5(8):1475-85. doi: 10.3390/toxins5081475. Toxins (Basel). 2013. PMID: 23965431 Free PMC article.
Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, Millward MJ, Bishop JF, Clarke SJ. Rivory LP, et al. Clin Cancer Res. 2000 Sep;6(9):3480-5. Clin Cancer Res. 2000. PMID: 10999732 Free article. Clinical Trial.
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A. Mathijssen RH, et al. J Natl Cancer Inst. 2004 Nov 3;96(21):1585-92. doi: 10.1093/jnci/djh298. J Natl Cancer Inst. 2004. PMID: 15523087
Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Paine MF, et al. Clin Pharmacol Ther. 2002 Nov;72(5):524-35. doi: 10.1067/mcp.2002.128387. Clin Pharmacol Ther. 2002. PMID: 12426516 Free article.
Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
Lemahieu WP, Maes BD, Ghoos Y, Rutgeerts P, Verbeke K, Vanrenterghem Y. Lemahieu WP, et al. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G470-82. doi: 10.1152/ajpgi.00028.2003. Am J Physiol Gastrointest Liver Physiol. 2003. PMID: 12909563 Free article.
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. Hirth J, et al. Clin Cancer Res. 2000 Apr;6(4):1255-8. Clin Cancer Res. 2000. PMID: 10778948 Free article. Clinical Trial.
In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4.
Nicandro JP, Tsourounis C, Frassetto L, Guglielmo BJ. Nicandro JP, et al. J Herb Pharmacother. 2007;7(1):39-56. J Herb Pharmacother. 2007. PMID: 17594986 Clinical Trial.
86 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page